L
Lentitek is developing methods to enhance the production yield of viral vectors used in gene therapies and CAR-T cell therapies by over tenfold. This improvement aims to significantly lower production costs, enabling wider access to these life-saving treatments for patients in need.
Updated 20 months ago
Funding
$390K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Lentitek is developing methods to enhance the production yield of viral vectors used in gene therapies and CAR-T cell therapies by over tenfold. This improvement aims to significantly lower production costs, enabling wider access to these life-saving treatments for patients in need.